DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF
Authors:
- Nuria Gutierrez-PratNGNuria Gutierrez-Prat
- Hedwig L ZubererHZHedwig L Zuberer
- Luca ManganoLMLuca Mangano
- Zahra KarimaddiniZKZahra Karimaddini
- Luise WolfLWLuise Wolf
- Stefka TyanovaSTStefka Tyanova
- Lisa C WellingerLWLisa C Wellinger
- Daniel MarbachDMDaniel Marbach
- Piergiorgio PettazzoniPPPiergiorgio Pettazzoni
- Daniel RohleDRDaniel Rohle
Open Access
- 17 May 2022
- journal article
- research article
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 5 (9) , e202101235
Abstract
MAPK inhibitors (MAPKi) remain an important component of the standard of care for metastatic melanoma. However, acquired resistance to these drugs limits their therapeutic benefit. Tumor cells can become refractory to MAPKi by reactivation of ERK. When this happens, tumors often become sensitive to drug withdrawal. This drug addiction phenotype results from the hyperactivation of the oncogenic pathway, a phenomenon commonly referred to as oncogene overdose. Several feedback mechanisms are involved in regulating ERK signaling. However, the genes that serve as gatekeepers of oncogene overdose in mutant melanoma remain unknown. Here, we demonstrate that depletion of the ERK phosphatase, DUSP4, leads to toxic levels of MAPK activation in both drug-naive and drug-resistant mutant melanoma cells. Importantly, ERK hyperactivation is associated with down-regulation of lineage-defining genes including MITF. Our results offer an alternative therapeutic strategy to treat mutant melanoma patients with acquired MAPKi resistance and those unable to tolerate MAPKi.Keywords
Funding Information
- Roche Postdoctoral Fellowship Program
This publication has 61 references indexed in Scilit:
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibitionOncogene, 2012
- The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cellsExperimental Cell Research, 2011
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanomaBMC Medicine, 2010
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Mitf regulation of Dia1 controls melanoma proliferation and invasivenessGenes & Development, 2006
- Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signaturePigment Cell Research, 2006
- Both Nuclear-Cytoplasmic Shuttling of the Dual Specificity Phosphatase MKP-3 and Its Ability to Anchor MAP Kinase in the Cytoplasm Are Mediated by a Conserved Nuclear Export SignalJournal of Biological Chemistry, 2004